Conferencia de consenso sobre los anticonceptivos orales combinados y las enfermedades cardiovasculares
DOI:
https://doi.org/10.18597/rcog.1010Resumen
Desde la utilización en los años 60 de anticonceptivos combinados orales, muchos datos han sido recolectados por el mundo entero, y los anticonceptivos combinados por vía oral (ACO) representan hoy en día el grupo de agentes farmacológicos más investigado. En nuestros días, los ACO se utilizan por más de 90 millones de mujeres en el mundo entero y ofrecen a estas mujeres beneficios para la salud inadecuadamente apreciados. Las mujeres beneficían no sólo de la eficacia de los ACO para la prevención de un embarazo no deseado sino también de la prevención de anemia, de dismenorrea y de reglas abundantes (1), y de una disminución significante de algunos cánceres ginecológicos, o sea el cáncer del endometrio y él del ovario (2).
Referencias bibliográficas
Peterson H.B., Lee N.C .. The health effects of oral contraceptives: misperceptions, controversies, and continuing good news. Clin Obstet Gynecol 1989;32:339-55.
Schlesselman J.J . Cancer of the breas! and reproductive tract in relation to use of oral contraceptives. Contraception 1989;40:1-38.
WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995a;346; 1582-8.
WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1997;349: 1202-9.
WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet l995b;348:498-505 .
WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre case-control study. Lancet 1996;348:505-510.
Spitzer W., Lewis 'M., Heinemann L., et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br. Med J. 1996; 312:83-8.
Lewis M., Spitzer H., Heinemann L. et al. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Br Med J 1996b;312:88-90.
Lidegaard 0., Edstrom B., Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception 1998;57 :291-301.
Lidegaard 0., Kreiner S. Cerebral thrombosis and oral contraceptives. A case-control study. Contraception 1998;57:303-14.
Jick H., Jick S., Gurewich V., Myers M., Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet 1995;346: 1589-93.
Farmer R., Lawrenson R., Thompson C., Kennedy J., Hambleton R. Population based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-8.
Farmer R., Presten T. The risk of venous thromboembolism associated with low oestrogen dose oral contraceptives. J Obstet Gynecol. 1995;15:195-200.
Gerstman B., Piper J., Tomita D., Ferguson W., Stadel B., Lundin F. Oral contraceptive dose and the risk of deep venous thromboembolic disease. Am. J. Epidemiol. 1991;133:32-7.
Suissa S., Blais L., Spitzer W., Cusson J. First-time use of newer oral contraceptives and the risk of venous thrombocmbolism. Contraception 1997 ;56: 128-32.
Winkler U. Blood coagulation and oral contraceptives: a critical review. Contraception 1998;57:203-9.
Farley T., Collins J., Schlesselman J. Hormonal contraception and the risk of cardiovascular disease: An international perspective. Contraception 1998;57 :211-30.
WHO Scientific Group on Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and steroid hormone contraception: a report of a WHO scientific group. WHO technical report series;877. 1997:Geneva.
Lewis M., Heinemann L, et al. The increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational research. Contraception 1996;45:5-13.
WHO. Improving access to quality care in family planning: medical eligibility criteria for contraceptive use. Geneva, WHO, Family and Reproductive Health 1996.
Cómo citar
Descargas
Descargas
Publicado
Número
Sección
| Estadísticas de artículo | |
|---|---|
| Vistas de resúmenes | |
| Vistas de PDF | |
| Descargas de PDF | |
| Vistas de HTML | |
| Otras vistas | |
